Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis

Indian Journal of Pharmacology

Volumn 45, Issue 5, 2013, Pages 536-537

  Deoghare, Shashank ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BEDAQUILINE; ISONIAZID; PLACEBO; RIFAMPICIN; RIFAPENTINE;

AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; CHEMOTHERAPY; DIRECTLY OBSERVED THERAPY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HEMOPTYSIS; HUMAN; INCIDENCE; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SPUTUM CULTURE; TABLET; THORAX PAIN; TREATMENT DURATION;

ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; DIARYLQUINOLINES; DRUG APPROVAL; HUMANS; INDIA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84884558821     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.117765     Document Type: Letter

References (9)

1. FDA news release. 2012 Dec 31. Available from: Http://www.fda.gov/ NewsEvents/ Newsroom/PressAnnouncements/ucm333695.htm [Last accessed on 2013 Feb 15].
2. National Research Council. Ending neglect: The elimination of tuberculosis in the United States. Washington, DC: The National Academies Press; 2000
3. World Health Organization (WHO). Global Tuberculosis Report 2012. Available from: Http://www.who.int/tb/publications/global-report/gtbr12-main.pdf [Last accessed on 2013 Feb 15].
4. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007;3:323-24
5. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, Guillemont J, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009;53:1290-2
6. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007;51:4202-04
7. U.S. Food and Drug Administration. SIRTURO Prescribing Information. Available from: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 204384s000lbl. pdf [Last accessed on 2013 Jun 23].
8. U.S. Food and Drug Administration. CFR - Code of Federal Regulations Title 21 Part 314 Subpart H. Available from: Http://www.accessdata.fda.gov/ scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?CFRPart = 314andshowFR = 1andsubpartNode = 21:5.0.1.1.4.8 [Last accessed on 2013 June 23].
9. U.S. Food and Drug Administration. NDA 204-384 Deputy Division Director Summary Review. Available from: Http://www.accessdata.fda.gov/drugsatfda- docs/nda/2012/204384Orig1s000SumR.pdf [Last accessed on 2013 June 23].